Yet despite decades of research, no treatment has been created that arrests Alzheimer’s cognitive deterioration, let alone ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

Xenon is one of the six noble gases. Its name derives from the Greek word for “strange”. In medicine, it has been used as an ...

Alzheimer’s disease is currently the third-leading cause of death among seniors in the U.S., following cardiovascular disease ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease ... treatment decisions for healthcare providers. There are safety ...

Fact checked by Nick Blackmer By 2060, nearly 14 million Americans may be living with Alzheimer’s disease. We still don’t ...

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD ...

on the primary endpoint of the Clinical Dementia Rating-Sum of Boxes (CDR-SB) global cognitive and functional scale. Over three years of treatment across the Clarity AD core study and LTE ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression ... although ARIA can occur at any time, and patients ...

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in the U.S.